Used in research to inhibit geranylgeranyltransferase I, an enzyme involved in post-translational modification of certain proteins like Rho and Rac. By blocking this enzyme, GGTI-2133 disrupts the membrane localization and function of these signaling proteins, which are implicated in cancer cell proliferation, survival, and metastasis. It is primarily employed in studies exploring targeted cancer therapies, especially in models of solid tumors and hematologic malignancies. Its application helps elucidate the role of protein prenylation in disease pathways and assesses potential therapeutic strategies aimed at the mevalonate pathway.